Initiation and adaptation: A paradigm for understanding psychotropic drug action

American Journal of Psychiatry

Volumn 153, Issue 2, 1996, Pages 151-162

  Hyman, Steven E ^a   Nestler, Eric J ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE DERIVATIVE; ANTIDEPRESSANT AGENT; COCAINE; LITHIUM; PSYCHOTROPIC AGENT;

ADAPTATION; ADDICTION; ARTICLE; BRAIN FUNCTION; DRUG ABUSE; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION; GENETIC REGULATION; HUMAN; NERVE CELL PLASTICITY; NEUROBIOLOGY; NEUROTRANSMITTER RELEASE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 0030032338     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.153.2.151     Document Type: Article

References (49)

1. Sulser F, Vetulani J, Mobley PL: Mode of action of antidepressant drugs. Biochem Pharmacol 1978; 27:257-261
2. Menkes DB, Aghajanian GK, McCall RB: Chrome antidepressant treatment enhances α-adrenergic and serotonergic responses in the facial nucleus. Life Sci 1980; 27:45-55
3. 2-adrenergic receptors after chronic desipramine treatment. Life Sci 1980; 27:1864-1876
4. Heninger GR, Charney DS: Mechanism of action of antidepressant treatments: implications for the etiology and treatment of depressive disorders, in Psychopharmacology: The Third Generation of Progress. Edited by Meltzer HY. New York, Raven Press, 1987, pp 535-544
5. Sulser F: New perspectives on the molecular pharmacology of affective disorders. Eur Arch Psychiatr Neurol Sci 1989; 238: 231-239
6. Kuhar MJ, Ritz MC, Boja JW: The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci 1991; 14: 299-302
7. Segal DS, Mandell AJ: Long-term administration of amphetamine: progressive augmentation of motor activity and stereotypy. Pharmacol Biochem Behav 1974; 2:249-255
8. Robinson TE, Jurson PA, Bennett JA, Bentgen KM: Persistent sensitizanon of dopamine neurotransmission in ventral striatum (nucleus accumbens) produced by prior experience with (+)-amphetamine: a microdialysis study in freely moving rats. Brain Res 1988; 462:211-222
9. DiChiara G, Imperato A: Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 1988; 85: 5274-5278
10. Koob GF, Bloom FE: Cellular and molecular mechanisms of drug dependence. Science 1988; 242:715-723
11. Wise RA: The role of reward pathways in the development of drug dependence, in Psychotropic Drugs of Abuse. Edited by Balfour DJK. Oxford, Pergamon Press, 1990, pp 23-57
12. Koob GF: Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 1992; 13:177-184
13. Self DW, Nestler EJ: Molecular mechanisms of drug reinforcement and addiction. Annu Rev Neurosci 1995; 18:463-495
14. Bergman J, Kamien JB, Spealman RD: Antagonism of cocaine self-administration by selective dopamine D1 and D2 antagonists. Behav Pharmacol 1989; 1:355-363
15. Mansour A, Khachaturian H, Lewis ME, Akil H, Watson SJ: Autoradiographic differentiation of mu, delta, and kappa receptors in the rat forebrain and mid-brain. J Neurosci 1987; 7: 2445-2464
16. Mansour A, Fox CA, Burke S, Meng F, Thompson RC, Akil H, Watson SJ: Mu, delta, and kappa opioid receptor mRNA expression in the rat CNS: an in situ hybridization study. J Comp Neurol 1994; 350:412-438
17. Johnson SW, North RA: Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci 1992; 12: 483-488
18. Pickel VM, Chan J, Sesack SR: Cellular substrates for interactions between dynorphin terminals and dopamine dendrites in rat ventral tegmental area and substantia nigra. Brain Res 1993; 602:275-289
19. Nestler EJ: Molecular mechanisms of drug addiction. J Neurosci 1992; 12:2439-2450
20. Nestler EJ, Alreja M, Aghajanian GK: Molecular and cellular mechanisms of opiate action: studies in the rat locus coeruleus. Brain Res Bull 1994; 5:521-528
21. Aghajanian G: Tolerance of locus coeruleus neurons to morphine and suppression of withdrawal response by clonidine. Nature 1978; 267:186-188
22. Maldonado R, Stinus L, Gold LH, Koob GF: Role of different brain structures in the expression of the physical morphine withdrawal syndrome. J Pharmacol Exp Ther 1992; 261:669-677
23. Robinson TE, Berridge KC: The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev 1993; 18:247-291
24. Hyman SE, Nestler EJ: The Molecular Foundations of Psychiatry. Washington, DC, American Psychiatric Press, 1993
25. Lefkowitz RJ: G protein-coupled receptor kinases. Cell 1993; 74: 409-412
26. Hyman SE, Comb M, Lin YS, Pearlberg J, Green MR, Goodman HM: A common trans-acting factor is required for cyclic AMP-induction of multiple neurotransmitter-related genes. Mol Cell Biol 1988; 8:4225-4233
27. Montminy MR, Gonzalez GA, Yamamoto KK: Regulation of cAMP-mducible genes by CREB. Trends Neurosci 1990; 13:184-188
28. Gonzalez GA, Montminy MR: Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at Serine 133. Cell 1989; 59:675-680
29. Konradi C, Cole RL, Heckers S, Hyman SE: Amphetamine regulates gene expression in rat striatum via transcription factor CREB. J Neurosci 1994; 14:5623-5634
30. Douglass J, McKinzie AA, Pollock KM: Identification of multiple DNA elements regulating basal and protein kinase A-induced transcriptional expression of the rat prodynorphin gene. Mol Endocrinol 1994; 8:333-344
31. Cole RL, Konradi C, Douglass J, Hyman SE: Neuronal adaptation to amphetamine and dopamine: molecular mechanisms of prodynorphin gene regulation in rat striatum. Neuron 1995; 14: 813-823
32. Hanson GR, Merchant KM, Letter AA, Bush L, Gibb JW: Characterization of methamphetamine effects on the striato-nigral dynorphin system. Eur J Pharmacol 1988; 155:11-18
33. Hurd YL, Herkenham M: Molecular alterations in the neostriatum of human cocaine addicts. Synapse 1993; 13:357-369
34. Chavkin C, James IF, Goldstein A: Dynorphin is a specific endogenous ligand for the k-opioid receptor. Science 1982; 215:413-415
35. Corbett AD, Paterson SJ, McKnight AT, Magnan J, Kosterlitz HW: Dynorphin 1-8 and dynorphin 1-9 are ligands for the kappa-subtype of opiate receptor. Nature 1982; 299:79-81
36. Spanagel R, Herz A, Shippenberg TS: The effects of opioid peptides on dopamine release in the nucleus accumbens: an in vivo microdialysis study. J Neurochem 1990; 55:1734-1740
37. Steiner H, Gerfen CR: Cocaine-induced c-fos messenger RNA is inversely related to dynorphin expression in striatum. J Neurosci 1993; 13:5066-5081
38. Terwilliger RZ, Beitner-Johnson D, Sevarino KA, Crain SM, Nestler EJ: A general role for adaptations in G-proteins and the cyclic AMP system in mediating the chronic actions of morphine and cocaine on neuronal function. Brain Res 1991; 548:100-110
39. Nestler EJ, Hope BT, Windell KL: Drug addiction: a model for the molecular basis of neural plasticity. Neuron 1993; 11:995-1006
40. Self DW, Terwilliger RZ, Nestler EJ, Stein L: Inactivation of Gi and Go proteins in nucleus accumbens reduces both cocaine and heroin reinforcement. J Neurosci 1994; 14:6239-6247
41. Graybiel AM, Moratalla R, Robertson HA: Amphetamine and cocaine induce drug-specific activation of the c-fos gene in striosome-matrix compartments and limbic subdivisions of the striatum. Proc Natl Acad Sci USA 1990; 87:6912-6916
42. Young ST, Porrino LJ, Iadarola MJ: Cocaine induces striatal c-fos-immunoreactive proteins via dopammergic D1 receptors. Proc Natl Acad Sci USA 1991; 88:1291-1295
43. Hope B, Kosofsky B, Hyman SE, Nestler EJ: Regulation of immediate early gene expression and AP-1 binding by chronic cocaine in the rat nucleus accumbens. Proc Natl Acad Sci USA 1992; 89:5764-5768
44. Nguyen TV, Kosofsky B, Birnbaum R, Cohen BM, Hyman SE: Differential expression of c-fos and zif268 in rat striatum after haloperidol, clozapine, and amphetamine. Proc Natl Acad Sci USA 1992; 89:4270-4274
45. Hope BT, Nye HE, Kelz MB, Self DW, Iadarola MJ, Nakabeppu Y, Duman RS, Nestler EJ: Induction of a long-lasting AP-1 complex composed of altered Fos-like proteins in brain by chronic cocaine and other chronic treatments. Neuron 1994; 13:1235-1244
46. Foote SL, Morrison JH: Extrathalamic modulation of cortical function. Annu Rev Neurosci 1987; 10:67-95
47. Schultz JE, Siggins GR, Schocker FW: Effects of prolonged treatment with lithium and tricyclic antidepressants on discharge frequency, norepinephrine responses and beta receptor binding in rat cerebellum: electrophysiological and biochemical comparison. J Pharmacol Exp Ther 1981; 216:28-38
48. Blier P, de Montigny C: Current advances and trends in the treatment of depression. Trends Pharmacol Sci 1994; 15:220-226
49. Rosin DL, Melia K, Knorr AM, Nestler EJ, Roth RH, Duman RS: Chronic imipramine administration alters the activity and phosphorylation state of tyrosine hydroxylase in dopaminergic regions of rat brain. Neuropsychopharmacology 1995; 12:113-121